Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Copaxone Prescribers for Multiple Sclerosis

Articles with lock require a subscription to GLG News | Request a free trial
June 4, 2007
Urgent need for clinical trials in ALS
Analysis of: Avicena Highlights Key Collaborators in Amyotrophic Lateral Sclerosis (ALS) Dose Escalation Study | pharmalive.com
Author: GLG Expert Contributor
There is not much information of the drug ALS-02 in the paper. The term neuroprotection is defined not very well and describes a great number of different molecular mechanisms. The low number of patients will not allow implications for clinical efficacy.
May 30, 2007
Pulsed radiofrequency (PRF) in treating chronic back pain seems effective.
Analysis of: New Treatment Offers Relief from Chronic Back Pain - Study Suggests Safe Treatment for a Variety of Conditions | www.medicalnewstoday.com
Author: GLG Expert Contributor
(1) Chronic back pain is a challenge to treat with limited options. (2) The emergence of new therapies to help support efforts at physiotherapy are certainly hopeful signs for those with refractory pain. (3) There are concerns about this specific treatment, PRF.
May 28, 2007
Pulsed radiofrequency (PRF) in treating chronic back pain seems effective.
Analysis of: New Treatment Offers Relief from Chronic Back Pain - Study Suggests Safe Treatment for a Variety of Conditions | www.medicalnewstoday.com
Author: GLG Expert Contributor
(1) Chronic back pain is a challenge to treat with limited options. (2) The emergence of new therapies to help support efforts at physiotherapy are certainly hopeful signs for those with refractory pain. (3) There are concerns about this specific treatment, PRF.
May 3, 2007
TRA-SCH 530348 in preventing vascular thrombotic events
Analysis of: Major phase 3 program planned for new antiplatelet drug | www.theheart.org
Author: GLG Expert Contributor
(1) TRA-SCH 530348 has a novel mechanism of action. (2) Many antiplatelet agents (and anticoagulation therapies) are available with differences based on ability to prevent clotting and risk of systemic hemorrhage. (3) Unclear what the benefits or risks of new agents will be until assessed in controlled...
December 5, 2006
Reliance on newer antipsychotics for behavior management questioned
Analysis of: NEWER ANTIPSYCHOTICS FALL SHORT FOR MANY WITH ALZHEIMER'S DEMENTIA, NIMH STUDY FINDS. | www.neurotodayonline.com
Author: GLG Expert Contributor
Newer antipsychotics have been relied on for behavioral management in dementia, given presumed beneficial side effect profile.Study refutes this clinical idea.
December 5, 2006
Personalized Medicine
Analysis of: Personalized Medicine Promises Tailor-Made Diagnoses, Treatment | news.nationalgeographic.com
Author: GLG Expert Contributor
Emerging pharmaceutical technology.Prescribing unique treatment specific for each patient.Possibly removing trial and error prescribing with more analytical approach.
October 30, 2006
FDA approval for severe Alzheimer's disease
Analysis of: Aricept (donepezil) Wins Indication for Severe Alzheimer's | www.medpagetoday.com
Author: GLG Expert Contributor
It is long waited decision. I have been using donepezil for last 4 to 5 years in moderate to severe Alzheimer's disease with good results. Only, I did not have statistical data.

Previous Page : 1 211 to 17 of 17

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T05:45:17.133